Get the Daily Brief
Latest Biotech News
PacBio Narrows Focus: Sells Short‑Read Assets to Illumina for $48.1M
Pacific Biosciences sold select short‑read sequencing intellectual property and assets (including technology from Apton/Omniome Onso) to Illumina for $48.1 million, saying the move sharpens its...
Twist’s Revenue Rises 17% as AI‑Enabled Discovery Drives New Orders
Twist Bioscience reported fiscal Q1 revenue of $103.7 million, a 17% year‑on‑year increase, and credited growth to its DNA synthesis and protein solutions business and new AI‑enabled therapeutic...
GSK Returns RNA Editing Rights to Wave: Wave Reclaims Lead Asset
GSK returned global rights for Wave Life Sciences’ RNA editing program WVE‑006 (AATD) to Wave, removing itself as development partner and restoring full control to Wave. Wave said it will pursue...
FDA Pauses Regenxbio Trials After Patient Cancer Case: Clinical Holds Raised
Regulatory scrutiny has halted parts of Regenxbio’s gene therapy program after a patient in one study developed cancer, prompting the FDA to place holds on two trials. The agency’s action requires...
Twist’s AI push pays off: Q1 revenue climbs 17%
Twist Bioscience reported fiscal Q1 revenue of $103.7 million, a 17% year‑over‑year increase driven by growth in DNA synthesis and an emergent AI‑enabled therapeutic discovery business. The...
PacBio pares assets: short‑read tech sold to Illumina for cash
Pacific Biosciences sold select short‑read sequencing intellectual property and related assets to Illumina for $50 million in cash, receiving about $48.1 million net after contingent payments,...
Roche/Genentech bet on Sanegene RNAi: multibillion‑dollar upside
SanegeneBio struck licensing agreements with Roche/Genentech for an RNAi program that include a $200 million upfront payment and potential for up to roughly $1.5–1.7 billion in development and...
Natera seeks FDA PMA for Signatera MRD test in bladder cancer
Natera submitted a premarket approval (PMA) application for its Signatera CDx assay to the U.S. Food and Drug Administration as a companion diagnostic to guide adjuvant treatment decisions with...
FDA opens PreCheck submissions: drugmakers can pitch faster factory builds
The U.S. Food and Drug Administration opened submissions for its PreCheck program, inviting drugmakers to apply for a pathway intended to accelerate construction of domestic drug manufacturing...
Daiichi halts next‑gen ADC development as Datroway readout slips
Daiichi Sankyo announced it is stopping internal development of a next‑generation antibody‑drug conjugate (ADC) built on a second ADC platform, and the company has again delayed a Phase 3 readout...
FDA places Regenxbio trials on hold after patient cancer case
The FDA has placed clinical holds on two Regenxbio gene therapy studies after a patient in one program developed cancer, prompting the agency to pause enrollment and dosing while it reviews safety...
Skye recovers with CB1–GLP‑1 combo: 22.3% weight loss at 52 weeks
Skye Bioscience released 52‑week interim data from the extension phase of its Phase 2a CBeyond study showing the nimacimab (peripherally‑restricted CB1 inhibitor) plus semaglutide combination...
Sanofi’s venglustat splits results: Gaucher win, Fabry failure
Sanofi reported mixed Phase 3 results for its glucosylceramide synthase (GCS) inhibitor venglustat: the drug met its primary endpoint in Gaucher disease but failed a separate Phase 3 trial in...
Trace wins IND for nerve imaging agent: first‑in‑human trial cleared
Trace Biosciences received FDA IND clearance for LGW16‑03 (Nervetrace Dx), a nerve‑specific fluorescent imaging agent, enabling a first‑in‑human study to evaluate safety and intraoperative...
Roche returns to RNA: $200M upfront, $1.5B in milestones
Roche’s Genentech unit licensed a SanegeneBio RNAi program in a deal that pays $200 million upfront and up to $1.5 billion in development and commercialization milestones. The companies said Roche...
Sanofi’s GCS inhibitor: passes Gaucher, fails Fabry
Sanofi reported mixed Phase 3 results for its glucosylceramide synthase (GCS) inhibitor venglustat: the drug met primary endpoints in a Phase 3 trial for Gaucher disease but failed a separate...
FDA places holds on Regenxbio trials after cancer case
The FDA placed clinical holds on two Regenxbio gene therapy studies after a patient in one trial developed cancer, prompting regulators to pause enrollment and dosing while safety investigations...
mRNA tactic neutralizes haemozoin block in malaria models
Researchers published in Nature Microbiology that an mRNA vaccination approach overcame haemozoin‑mediated immune suppression and restored efficacy of whole‑parasite malaria vaccines in mice. The...
Intranasal H5N1 vaccine prevents infection in rodent models
Washington University investigators developed an intranasal adenoviral‑vectored H5N1 vaccine that protected mice and hamsters from infection and transmission in preclinical studies published in...
Skye posts 52‑week interim gain for nimacimab plus semaglutide
Skye Bioscience disclosed interim 52‑week results from the extension phase of its Phase 2a CBeyond study evaluating nimacimab (a peripherally‑restricted CB1 inhibitor antibody) in combination with...